ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1725

Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model

Yue Peng1, H. Mark Kenney2, Karen Bentley3, Lianping Xing4, Christopher T Ritchlin5 and Edward Schwarz3, 1University of Rochester Medical Center, Rochester, NY, 2University of Rochester School of Medicine and Dentistry, Henrietta, NY, 3University of Rochester, Rochester, NY, 4University of Rochester Medical Center, Webster, NY, 5University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY

Meeting: ACR Convergence 2023

Keywords: Animal Model, Bone Resorption, Inflammation, rheumatoid arthritis, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1713–1733) RA – Animal Models Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2). In studies to directly assess this relationship, we identified a novel population of intravascular MCs embedded in the cellular architecture of murine joint-draining popliteal lymphatic vessels (PLVs) (3), along with perivascular MCs surrounding the PLV. Here, we investigated the phenotypic differences between PLV perivascular and intravascular MCs to elucidate their respective roles in regulating lymphatic function and inflammatory-erosive arthritis through genetic ablation and pharmacologic inhibition of MCs.

Methods: PLVs from WT, TNF-Tg, and KitW-sh/W-sh (cKit-/-) mice (4), which have a selective hematopoietic deficit in MCs, were harvested for whole mount immunofluorescent microscopy (WMIFM) and toluidine blue histochemistry to identify MCs. In silico analyses were performed on single-cell RNA sequencing (scRNAseq) datasets of PLV MCs (5) vs MC populations identified in the Mouse Cell Atlas (6). Near-infrared indocyanine green (NIR-ICG) imaging quantified lymphatic clearance function. Longitudinal micro-computed tomography (μCT) assessed bone erosions, while H&E and TRAP histology evaluated synovitis and osteoclasts of the afferent ankle. MC deficiency was studied in cKit-/- x TNF-Tg mice (n=3), while MC inhibition was investigated in TNF-Tg mice treated with cromolyn sodium (CS; 3.15mg/g/day/i.p., n=6) vssaline (n=5) for 3 weeks.

Results: WMIFM of MC-tryptase (MCT) confirmed increased numbers of perivascular MCs in TNF-Tg mice, and their complete absence in cKit-/-mice (Fig. 1). In silico scRNAseq analysis revealed a distinct population of PLV MCs vs known MCs in other mouse organs. WMIFM further demonstrated unique molecular signatures of perivascular (MCT+/MCTP1+/MCTP5–) vs intravascular (MCT+/MCTP1–/MCPT5–) MCs (Fig. 2). Remarkably, both CS treatment and cKit-/- x TNF-Tg mice exhibited decreased ICG clearance corresponding with increased bone erosions and synovitis vs their TNF-Tg controls (Fig. 3).

Conclusion: In this work, we characterized unique intravascular MCTP1– MCs in a cellular niche within the tissue structure [BK1] of murine joint-draining PLVs. These intravascular MCs are distinct from known MC subtypes, including perivascular MCTP1+ MCs, which are increased in TNF-Tg and absent in cKit-/- mice. Interestingly, both global MC deletion and inhibition decreased lymphatic function and exacerbated joint disease in TNF-Tg mice. These findings suggest subtype-specific MC regulation of lymphatic function through distinct cellular phenotypes, where MCTP1– intravascular MCs provide a protective role and selective deletion of MCTP1+ perivascular MCs restored lymphatic drainage and ameliorated inflammatory-erosive arthritis.

Supporting image 1

Figure 1. Identification of intravascular MCs and increased numbers of MCT+ perivascular MCs in TNF-Tg mice. Longitudinal sections of PLVs obtained from WT mice were subjected to toluidine blue staining, and a 200x micrograph is shown highlighting a novel intravascular MC embedded within the lymphatic vessel wall (red arrow), situated between the layers of lymphatic endothelial and lymphatic muscle cells (A) (3). PLVs were harvested for WMIFM of αSMA (green) and MCT (red), and representative 200x images are shown for WT (B),TNF-Tg (C), cKit-/-(D) mice, which demonstrated a complete absence of MCT+ MCs in cKit-/- as confirmation of the genetic ablation in this model. Quantification of perivascular MCT+ cells showed a significant increase in MCs surrounding inflamed TNF-Tg PLVs, normalized to vessel length (E, n=8). Statistics: Unpaired Mann Whitney test (E); ***p < 0.001.

Supporting image 2

Figure 2. Identification of a unique MCT+/MCTP1-/MCPT5- PLV intravascular MC population. In silico datasets were used to extract MCs from a comprehensive scRNAseq dataset of 242k cells encompassing various organs in the Mouse Cell Atlas (6). The extraction was performed based on the expression of MC marker genes (Mcpt4, Cma1, Cpa3, Tpsb2, Kit, Fcer1a, Gata2) to subset MCs from other cell types. These MCs were subsequently integrated with the MCs from our previously published scRNAseq dataset of PLV tissue (5), reclustered, and shown as a UMAP. Notably, the PLV MCs (arrow) exhibited a distinct transcriptional pattern distinct from other MCs identified in the Mouse Cell Atlas (A). WMIFM was performed on PLVs for αSMA, MCT, MCPT1, and MCPT5, as described in Figure 1. A 400x image highlights the MCT+ intravascular MC (B, red arrow) embedded in gaps between αSMA+ lymphatic muscle cells, while a 200x image with 400x inset (white box) exhibits the MCPT1+ perivascular MC (pink arrow) and MCPT1- intravascular MC (white arrow) that exists within the αSMA- void (C). A 200x image with 400x inset (white box) demonstrates that both perivascular (red arrow) and intravascular (white arrow) MCs are MCPT5-negative (D).

Supporting image 3

Figure 3. Global MC deletion and inhibition with cromolyn sodium decrease lymphatic clearance and exacerbate inflammatory-erosive arthritis in TNF-Tg mice. KitW-sh/W-sh (cKit-/-) and TNF-Tg mice were crossed to generate TNF-Tg x cKit-/- cohorts (both C57BL/6 background). Male mice at 4.5 months of age underwent NIR-ICG imaging, which demonstrated a combinatorial reduction of lymphatic function in the setting of inflammation (TNF-Tg) and MC ablation (cKit-/-) (A). In TNF-Tg mice, the enhanced lymphatic deficiency with MC deletion was associated with increased bone erosions in the talus (green bone) of the afferent ankle joint, quantified by micro-CT with represented images provided (B, C). Histomorphometric analysis revealed a corresponding increase in synovial inflammation (D, H&E) and number of osteoclasts (E, TRAP) in the talus region of MC deficient TNF-Tg x cKit-/- mice, as shown by representative images (F). To evaluate the effects of MC inhibition, 4-month-old female TNF-Tg mice (n=10) were randomized to 3-weeks of placebo (PBS) or cromolyn sodium (CS) treatment (n = 5 mice/group; 10 limbs) based on baseline lymphatic clearance by NIR-ICG imaging. Terminal NIR-ICG and micro-CT imaging revealed significantly reduced lymphatic clearance (G) and midfoot bone volumes (H, I; green talus as representative image) with CS, respectively. Coinciding with the increased bone erosions, histomorphometry also showed increased synovial (J) and TRAP+ osteoclast area (K) with representative images provided (L). Statistics: unpaired t-test; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.


Disclosures: Y. Peng: None; H. Kenney: None; K. Bentley: None; L. Xing: None; C. Ritchlin: AbbVie, 2, 5, 6, Amgen, 2, BMS, 2, Eli Lilly, 2, Gilead, 2, Janssen, 2, Novartis, 2, Pfizer, 2, 5, 6, UCB, 2, 6; E. Schwarz: None.

To cite this abstract in AMA style:

Peng Y, Kenney H, Bentley K, Xing L, Ritchlin C, Schwarz E. Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/distinct-perivascular-and-intravascular-lymphatic-mast-cells-and-their-role-in-lymphatic-clearance-joint-inflammation-and-bone-erosion-in-the-tnf-transgenic-murine-arthritis-model/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/distinct-perivascular-and-intravascular-lymphatic-mast-cells-and-their-role-in-lymphatic-clearance-joint-inflammation-and-bone-erosion-in-the-tnf-transgenic-murine-arthritis-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology